RE:RE:RE:RE:Okanagan Falls site prepTo the point about CSE, there are many CSE-listed stocks that have jumped XXX% so being listed on the CSE is not necessarily a huge problem from a SP perspective. But I think Bluechip's SA comment from a few days ago addresses the SP issue very accurately and well:
"I don't understand the negativity towards the NHS clinics, it is a brilliant strategy to grow the customer base for medical cannabis and delop tailored strains with ever increasing margins. Also, Sunlife and others are proposing initial full coverage of 1500/patient. I assume the future national pharmacare will be the similar, so that will also drive the customer base. Until product arrives to the clinics, my expectation was if they could hold their own, as the doctor salaries alone were roughly 9.4m. For me, they are a California play and will have free reign there come third quarter once product starts rolling out. No legalization worries, or oversupply, etc. if and when descheduling occurs in the US, they will be one of the best positioned cannabis companies in North America. This is what will generate massive share growth, not whining about a timeline being too aggressive or concerns of nonprofit before they even grow a bud. Just my two cents, but the path is clear to me, but for some reason people are focussed on the short term, what have you done for me lately. Pederson is the mastermind here, years in the making, investors generally have not taken the time to map it all out."